Table 1 Basic characteristics of patients with HBV–ACLF received glucocorticoid treatment or not
Variables | Routine treatment group (n = 76) | Glucocorticoid treatment group (n = 204) | P |
|---|---|---|---|
Male sex, n (%) | 58 (76.32%) | 161 (78.92%) | 0.64 |
Age (year) | 38 (48–58) | 35 (45–55) | 0.1 |
HBeAg + n. (%) | 46 (60.53%) | 118 (57.84%) | 0.69 |
Log10 [HBV DNA] | 5.07 (4.21–6.23) | 4.73 (3.38–6.1) | 0.1 |
ALT (U/L) | 210.5 (105.75–533) | 172.5 (91–397.5) | 0.34 |
AST (U/L) | 176.5 (90.5–297.75) | 158.5 (97–388.75) | 0.64 |
GGT (U/L) | 85.5 (53.25–145.75) | 93 (59.5–153) | 0.22 |
AKP (U/L) | 130 (107.25–164.25) | 142.50 (116–174.75) | 0.17 |
TBIL (μmol/L) | 232.9 (152.33–405.28) | 276.70 (184.58–415.03) | 0.17 |
ALB (g/L) | 30.9 (26.75–34.5) | 31.70 (29–34.78) | 0.27 |
INR | 1.88 (1.69–2.33) | 1.82 (1.61–2.33) | 0.28 |
Cr (μmol/L) | 67 (53.25–80) | 66 (57–76.75) | 0.83 |
WBC (× 109/L) | 6.92 (4.45–10.22) | 7.17 (4.73–9.34) | 0.85 |
HGB (g/L) | 125 (109–135.75) | 125 (113–140) | 0.86 |
PLT (× 109/L) | 99.5 (69–134.75) | 109.00(67.25–154.75) | 0.39 |
HE n. (%) | 24 (31.58%) | 62 (30.39%) | 0.85 |
Ascites n. (%) | 36 (47.39%) | 104 (50.98%) | 0.59 |
SIRS n. (%) | 27 (35.53%) | 64 (31.37%) | 0.51 |
MELD score | 21.52 (17.26–25.41) | 21.55 (18.34–25.01) | 0.78 |
CTP score | 10 (9–11) | 10 (9–11) | 0.52 |
90-day mortality | 45/76 (59.21%) | 86/204 (42.16%) | 0.01 |